ArticleInvestigative ophthalmology & visual science2025
Understanding How Low Luminance Visual Deficit Progresses With Advancing Diabetic Macular Ischemia and Diabetic Retinopathy.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Baseline Deep Capillary Plexus Ischemia Predicts Earlier Diabetic Retinopathy Complications Than Foveal Avascular Enlargement.American journal of ophthalmology · 2026Article
- Validation of Deep Capillary Plexus OCTA Metrics as Predictors of Diabetic Retinopathy Complications: A One-Year Longitudinal Study.Research square · 2026Article
- Qualitative and Quantitative Assessment of Restored Capillary Perfusion on OCT Angiography in Diabetic Macular Ischemia.Translational vision science & technology · 2026Article
- Baseline Nonperfusion and Deep Capillary Plexus Ischemia Predict Two-Year Retinal Nonperfusion Progression in Diabetic Retinopathy.Investigative ophthalmology & visual science · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Purpose: To assess whether low luminance deficit (LLD) correlates with diabetic macular ischemia on optical coherence tomography angiography (OCTA). Methods: Best-corrected visual acuity (BCVA) and low luminance visual acuity (LLVA; using 2.0-log unit neutral density filter) were assessed with Early Treatment Diabetic Retinopathy Study (ETDRS) charts and recorded as ETDRS letter scores. Low-luminance deficit (LLD) was calculated as BCVA - LLVA. From OCTA 3 × 3 mm scans, geometric perfusion deficits (GPD), vessel length density (VLD), and vessel density (VD) in deep (DCP) and superficial (SCP) capillary plexuses were quantified. Linear regression analyzed associations between LLD and OCTA metrics. Results: The study included 91 non-referable (no/mild DR), 94 referable (moderate/severe nonproliferative DR, treatment naïve PDR), and 76 quiescent laser-treated PDR eyes, all without macular edema. BCVA (86.6 ± 5.02, 83.5 ± 5.95, 76.8 ± 9.52; P < 0.001) and LLVA (78.5 ± 5.18, 73.8 ± 7.84, 69.5 ± 9.61; P < 0.001) declined with increasing DR severity. LLD was higher in referable DR (9.8 ± 4.4) versus non-referable DR (8.1 ± 3.12) and quiescent PDR eyes (7.3 ± 3.52; P < 0.001). LLD was negatively associated with DCP VLD in the entire cohort (referable and non-referable DR; β = -3.01; P = 0.030) and with DCP GPD in quiescent PDR eyes (β = -1.77; P = 0.032). Conclusions: Both BCVA and LLVA decline with DR progression; however, distinct LLD patterns have emerged across DR stages. In referable DR, LLD is larger as a result of LLVA decline, whereas in quiescent PDR smaller LLD reflects a greater decline in BCVA. These findings emphasize the nuanced relationship of LLD with photopic and mesopic visual functions, which decline in distinct patterns across DR stages. LLD may serve as a simple and practical tool for monitoring macular ischemia progression in diabetic eyes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.